tiprankstipranks
Trinity Biotech’s Q3 2024 Revenue and Strategic Growth
Company Announcements

Trinity Biotech’s Q3 2024 Revenue and Strategic Growth

Trinity Biotech (TRIB) has released an update.

Don't Miss Our Christmas Offers:

Trinity Biotech reported a 3% increase in Q3 2024 revenue to $15.2 million, driven by strong demand for its TrinScreen HIV business. The company also highlighted significant growth in its Point-of-Care product revenue, which surged by 60% year-over-year. Furthermore, Trinity Biotech is progressing with strategic initiatives aimed at enhancing profitability, including consolidating manufacturing operations and expanding into the oncology diagnostics market.

For further insights into TRIB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskTrinity Biotech Gains WHO Approval for Offshore HIV Test Manufacturing
TheFlyTrinity Biotech gets approval from WHO for TrinScreen, Uni-Gold manufacturing
TipRanks Auto-Generated NewsdeskTrinity Biotech Files Prospectus for $1 Million ADS Offering
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App